public/data/source_tsvs/ClearityFoundationClinicalTrials_INTERACTIONS.tsv
Molecular Target Entrez Gene Name Enterez Gene Id Drug name Other drug name Pubchem name CID SID Interaction type Mode of action Clinical Trial ID(s) Detail Phase Include this entry? Comments
ALK1 ligands (TGFbeta family) ACVRL1 94 Dalantercept ACE-041, ALK1-Fc Fusion Protein ACE-041 Dalantercept N/A 160693095 inhibitor ALK1 inhibitor NCT01720173 Recurrent epithelial ovarian cancer A Phase II Evaluation of Dalantercept (NSC #75172, IND #116598), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
AKT1-3 AKT1 207 GSK2141795 N/A N/A N/A N/A inhibitor Akt inhibitor NCT01138085 Advanced Solid Tumors A Phase I Dose Escalation Open-Label Safety and Pharmacokinetic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 in Subjects With Solid Tumors (Part 1) and in Subjects With Pancreatic Cancer, Endometrial Cancer or Colorectal Cancer (Part 2) I 1
AKT1-3 AKT1 207 AZD5363 Akt inhibitor AZD5363 AZD5363 25227436 N/A inhibitor Akt inhibitor NCT01226316 Advanced Solid Tumors; Ovarian Cancer; AKT1 or PIK3CA mutant cancers A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies. I 1
AKT1-3 AKT1 207 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01245205 Advanced Solid Tumors A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer I 1
AKT1-3 AKT1 207 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01295632 Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer I 1
AKT1-3 AKT1 207 ARQ092 N/A N/A N/A N/A inhibitor pan-AKT inhibitor NCT01473095 Advanced solid tumors Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors I 1
AKT1-3 AKT1 207 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01480154 Advanced Solid Tumors A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis I 1
AKT1-3 AKT1 207 GSK2141795 N/A N/A N/A N/A inhibitor Akt inhibitor NCT01902173 BRAF V600 mutant metastatic cancer Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With the BRAF Inhibitor Dabrafenib in Patients With BRAF Mutant Cancer I 1
AKT1-3 AKT1 207 SAR260301 N/A N/A N/A N/A inhibitor Akt inhibitor NCT01673737 Advanced Solid Tumors A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma I/Ib 1
AKT1-3 AKT1 207 Afuresertib GSK2110183 Afuresertib hydrochloride 46843056 N/A inhibitor Akt inhibitor NCT01653912 Recurrent platinum-resistant ovarian cancer An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer I/II 1
AKT1-3 AKT1 207 Triciribine API-2, triciribine phosphate, tricyclic nucleoside, tricycloside phosphate Triciribine 65399 N/A inhibitor Akt inhibitor NCT01690468 recurrent or persistent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma Leveraging a Clinico-Genomic Database to Match Patients to a Trial of Triciribine and Carboplatin: Changing Paradigms in Ovarian Cancer Clinical Research I/II 1
AKT1-3 AKT1 207 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01235897 Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab Ib 1
AKT1-3 AKT1 207 GDC-0068 Akt Inhibitor GDC-0068 GDC-0068 24788740 N/A inhibitor Akt inhibitor NCT01562275 Locally advanced or metastatic solid tumors A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors Ib 1
AKT1-3 AKT2 208 GSK2141795 N/A N/A N/A N/A inhibitor Akt inhibitor NCT01138085 Advanced Solid Tumors A Phase I Dose Escalation Open-Label Safety and Pharmacokinetic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 in Subjects With Solid Tumors (Part 1) and in Subjects With Pancreatic Cancer, Endometrial Cancer or Colorectal Cancer (Part 2) I 1
AKT1-3 AKT2 208 AZD5363 Akt inhibitor AZD5363 AZD5363 25227436 N/A inhibitor Akt inhibitor NCT01226316 Advanced Solid Tumors; Ovarian Cancer; AKT1 or PIK3CA mutant cancers A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies. I 1
AKT1-3 AKT2 208 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01245205 Advanced Solid Tumors A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer I 1 Lapatinib is approved for breast cancer
AKT1-3 AKT2 208 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01295632 Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer I 1
AKT1-3 AKT2 208 ARQ092 N/A N/A N/A N/A inhibitor pan-AKT inhibitor NCT01473095 Advanced solid tumors Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors I 1
AKT1-3 AKT2 208 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01480154 Advanced Solid Tumors A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis I 1
AKT1-3 AKT2 208 GSK2141795 N/A N/A N/A N/A inhibitor Akt inhibitor NCT01902173 BRAF V600 mutant metastatic cancer Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With the BRAF Inhibitor Dabrafenib in Patients With BRAF Mutant Cancer I 1
AKT1-3 AKT2 208 SAR260301 N/A N/A N/A N/A inhibitor Akt inhibitor NCT01673737 Advanced Solid Tumors A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma I/Ib 1
AKT1-3 AKT2 208 Afuresertib GSK2110183 Afuresertib hydrochloride 46843056 N/A inhibitor Akt inhibitor NCT01653912 Recurrent platinum-resistant ovarian cancer An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer I/II 1
AKT1-3 AKT2 208 Triciribine API-2, triciribine phosphate, tricyclic nucleoside, tricycloside phosphate Triciribine 65399 N/A inhibitor Akt inhibitor NCT01690468 recurrent or persistent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma Leveraging a Clinico-Genomic Database to Match Patients to a Trial of Triciribine and Carboplatin: Changing Paradigms in Ovarian Cancer Clinical Research I/II 1
AKT1-3 AKT2 208 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01235897 Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab Ib 1
AKT1-3 AKT2 208 GDC-0068 Akt Inhibitor GDC-0068 GDC-0068 24788740 N/A inhibitor Akt inhibitor NCT01562275 Locally advanced or metastatic solid tumors A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors Ib 1
AKT1-3 AKT3 10000 GSK2141795 N/A N/A N/A N/A inhibitor Akt inhibitor NCT01138085 Advanced Solid Tumors A Phase I Dose Escalation Open-Label Safety and Pharmacokinetic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 in Subjects With Solid Tumors (Part 1) and in Subjects With Pancreatic Cancer, Endometrial Cancer or Colorectal Cancer (Part 2) I 1
AKT1-3 AKT3 10000 AZD5363 Akt inhibitor AZD5363 AZD5363 25227436 N/A inhibitor Akt inhibitor NCT01226316 Advanced Solid Tumors; Ovarian Cancer; AKT1 or PIK3CA mutant cancers A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies. I 1
AKT1-3 AKT3 10000 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01245205 Advanced Solid Tumors A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer I 1
AKT1-3 AKT3 10000 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01295632 Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer I 1
AKT1-3 AKT3 10000 ARQ092 N/A N/A N/A N/A inhibitor pan-AKT inhibitor NCT01473095 Advanced solid tumors Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors I 1
AKT1-3 AKT3 10000 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01480154 Advanced Solid Tumors A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis I 1
AKT1-3 AKT3 10000 GSK2141795 N/A N/A N/A N/A inhibitor Akt inhibitor NCT01902173 BRAF V600 mutant metastatic cancer Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With the BRAF Inhibitor Dabrafenib in Patients With BRAF Mutant Cancer I 1
AKT1-3 AKT3 10000 SAR260301 N/A N/A N/A N/A inhibitor Akt inhibitor NCT01673737 Advanced Solid Tumors A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma I/Ib 1
AKT1-3 AKT3 10000 Afuresertib GSK2110183 Afuresertib hydrochloride 46843056 N/A inhibitor Akt inhibitor NCT01653912 Recurrent platinum-resistant ovarian cancer An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer I/II 1
AKT1-3 AKT3 10000 Triciribine API-2, triciribine phosphate, tricyclic nucleoside, tricycloside phosphate Triciribine 65399 N/A inhibitor Akt inhibitor NCT01690468 recurrent or persistent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma Leveraging a Clinico-Genomic Database to Match Patients to a Trial of Triciribine and Carboplatin: Changing Paradigms in Ovarian Cancer Clinical Research I/II 1
AKT1-3 AKT3 10000 MK2206 Akt Inhibitor MK2206 MK2206 46930998 N/A inhibitor Akt inhibitor NCT01235897 Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab Ib 1
AKT1-3 AKT3 10000 GDC-0068 Akt Inhibitor GDC-0068 GDC-0068 24788740 N/A inhibitor Akt inhibitor NCT01562275 Locally advanced or metastatic solid tumors A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors Ib 1
Ang1 ANGPT1 284 Trebaninib AMG 386 Trebaninib N/A 160671634 inhibitor Tie2R inhibitor NCT01281254 Recurrent ovarian cancer A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer III 1
Ang1 ANGPT1 284 Trebaninib AMG 386 Trebaninib N/A 160671634 inhibitor Tie2R inhibitor NCT01493505 Newly diagnosed stage III-IV ovarian epithelial cancer A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers III 1 Carboplatin is approved for ovarian cancer
Ang2 ANGPT2 285 MED13617 anti-Angiopoietin 2 mab N/A N/A N/A antagonist Angiopoietin 2 antagonist NCT01248949 Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors I 1
Gamma-secretase APH1A 51107 BMS-906024 N/A UNII-DRL23N424R 66550890 N/A inhibitor Gamma-secretase inhibitor NCT01292655 Advanced cancer Study to Evaluate the Safety and Tolerability of Weekly IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors I 1
Gamma-secretase APH1A 51107 MK0752 N/A MK-0752 9803433 N/A inhibitor Notch signaling pathway inhibitor NCT01295632 Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer I 1
Gamma-secretase APH1B 83464 BMS-906024 N/A UNII-DRL23N424R 66550890 N/A inhibitor Gamma-secretase inhibitor NCT01292655 Advanced cancer Study to Evaluate the Safety and Tolerability of Weekly IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors I 1
Gamma-secretase APH1B 83464 MK0752 N/A MK-0752 9803433 N/A inhibitor Notch signaling pathway inhibitor NCT01295632 Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer I 1
Aurora A Kinase AURKA 6790 AMG 900 Aurora Kinase Inhibitor AMG 900 AMG900 24856041 N/A inhibitor pan-Aurora kinase inhibitor NCT00858377 Advanced solid tumors A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors I 1
Aurora A kinase AURKA 6790 Alisertib MLN8237 ALISERTIB SODIUM 56843791 N/A inhibitor Aurora A kinase inhibitor NCT01094288 Advanced Solid Tumors A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen I 1
Aurora A Kinase AURKA 6790 ABT-384 N/A N/A N/A N/A inhibitor pan-Aurora Kinase inhibitor (B/C >A) NCT01110486 Advanced solid tumors A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors I 1
Aurora A kinase AURKA 6790 Alisertib MLN8237 ALISERTIB SODIUM 56843791 N/A inhibitor Aurora A kinase inhibitor NCT01639911 Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
Aurora A kinase AURKA 6790 Alisertib MLN8237 ALISERTIB SODIUM 56843791 N/A inhibitor Aurora A kinase inhibitor NCT01639911 Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
Aurora A kinase AURKA 6790 Alisertib MLN8237 ALISERTIB SODIUM 56843791 N/A inhibitor Aurora A kinase inhibitor NCT01091428 Recurrent epithelial ovarian carcinoma MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer I/II 1
Aurora A kinase AURKA 6790 Alisertib MLN8237 ALISERTIB SODIUM 56843791 N/A inhibitor Aurora A kinase inhibitor NCT01613261 Advanced Solid Tumors A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies Ib 1
Aurora A kinase AURKA 6790 Alisertib MLN8237 ALISERTIB SODIUM 56843791 N/A inhibitor Aurora A kinase inhibitor NCT01653028 Advanced ovarian carcinosarcoma Phase II Study of MLN8237 in Advanced / Metastatic Sarcoma II 1 'Aurora A kinase' is not found in Entrez by this name but it is there -> AURKA
Aurora A kinase AURKA 6790 ENMD-2076 N/A ENMD-2076 16041424 N/A inhibitor Aurora A and VEGFR/FGFR kinase inhibitor NCT01914510 Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas II 1
Aurora B Kinase AURKB 9212 AMG 900 Aurora Kinase Inhibitor AMG 900 AMG900 24856041 N/A inhibitor pan-Aurora kinase inhibitor NCT00858377 Advanced solid tumors A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors I 1
Aurora B Kinase AURKB 9212 ABT-384 N/A N/A N/A N/A inhibitor pan-Aurora Kinase inhibitor (B/C >A) NCT01110486 Advanced solid tumors A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors I 1
Aurora C Kinase AURKC 6795 AMG 900 Aurora Kinase Inhibitor AMG 900 AMG900 24856041 N/A inhibitor pan-Aurora kinase inhibitor NCT00858377 Advanced solid tumors A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors I 1
Aurora C Kinase AURKC 6795 ABT-384 N/A N/A N/A N/A inhibitor pan-Aurora Kinase inhibitor (B/C >A) NCT01110486 Advanced solid tumors A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors I 1
Bcl2 BCL2 596 Paclitaxel Albumin-Stabilized Nanoparticle Formulation ABI-007, Abraxane, nab-paclitaxel Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00313599 Advanced solid cancers A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane in Patients With Advanced Solid Tumors I 1 Paclitaxel nanoparticle
Bcl2 BCL2 596 Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation ABI-007, Abraxane, Anzatax, Asotax, Bristaxol, nab-paclitaxel, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00825201 Advanced cancer of the peritoneal cavity. Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity I 1 Albumin nanoparticle
Bcl2 BCL2 596 Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation ABI-007, Abraxane, Anzatax, Asotax, Bristaxol, nab-paclitaxel, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00825201 Advanced cancer of the peritoneal cavity. Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity I 1 Albumin-paclitaxel nanoparticle
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00989651 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer I 1 quadraple therapy
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01209195 Locally advanced/metastatic or recurrent epithelial ovarian cancer A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers I 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01248949 Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors I 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01256268 Metastatic or Recurrent Ovarian Cancer elegible for carbo-taxol treatment Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids I 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01366144 Recurrent or stage IV ovarian cancer An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors I 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01411410 Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy I 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01649336 Platinum resistant epithelial ovarian cancer A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer I 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01676753 Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression I 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01688791 Advanced Cancer A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Combinations in Adult Subjects With Advanced Cancers I 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01778803 Adv or refractory ovarian cancer A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer I 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01831089 Advanced solid tumors Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors I 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00976183 Stage III/IV ovarian cancer cancer, not have received chemotherapy yet Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma I/II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01091428 Recurrent epithelial ovarian carcinoma MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer I/II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01650376 Relapsed ovarian cancer Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients I/II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01653912 Recurrent platinum-resistant ovarian cancer An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer I/II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01696032 Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer I/II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01711970 Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Mllerian Cancer I/II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01235897 Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab Ib 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00585052 Platinum-refractory or -resistant ovarian cancer A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01097746 Newly diagnosed stage III, IV ovarian epithelial cancer First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01196429 Newly diagnosed stage III or stage IV clear cell ovarian cancer. Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01357161 Platinum-sensitive p53 mutant ovarian cancer A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01616303 Newly diagnosed advanced ovarian cancer Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma II 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01716715 Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER II 1
Bcl2 BCL2 596 Paclitaxel, Paclitaxel Poliglumex Anzatax, Asotax, Bristaxol, paclitaxel-polyglutamate polymer, polyglutamate paclitaxel, polyglutamic acid paclitaxel, Poly-L-Glutamic acid-Paclitaxel Conjugate, Praxel, Taxol, Taxol Konzentrat, TXL, Xyotax Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00108745 Stage III-IV ovarian epithelial cancer Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer III 1
Bcl2 BCL2 596 Paclitaxel, Paclitaxel Poliglumex Anzatax, Asotax, Bristaxol, paclitaxel-polyglutamate polymer, polyglutamate paclitaxel, polyglutamic acid paclitaxel, Poly-L-Glutamic acid-Paclitaxel Conjugate, Praxel, Taxol, Taxol Konzentrat, TXL, Xyotax Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00108745 Stage III-IV ovarian epithelial cancer Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer III 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00565851 Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer III 1 Bevacizumab is already approved for ovarian cancer
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00954174 Persistent or recurrent ovarian cancer Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer III 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01081262 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer III 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01167712 Stage III, IV ovarian epithelial cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer III 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01239732 Newly diagnosed advanced ovarian cncer Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma III 1 Bevacizumab is already approved for ovarian cancer
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01493505 Newly diagnosed stage III-IV ovarian epithelial cancer A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers III 1
Bcl2 BCL2 596 Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01849874 Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer III 1
IAP inhibitor BIRC2 329 Birinapant Smac Mimetic TL32711, TL32711 Birinapant 49836020 N/A antagonist inhibitor of apoptosis (IAP) antagonist NCT01681368 Platinum Resistant or Refractory Epithelial Ovarian Cancer Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal II 1
ALK1 ligands (TGFbeta family) BMP10 27302 Dalantercept ACE-041, ALK1-Fc Fusion Protein ACE-041 Dalantercept N/A 160693095 inhibitor ALK1 inhibitor NCT01720173 Recurrent epithelial ovarian cancer A Phase II Evaluation of Dalantercept (NSC #75172, IND #116598), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
RAF BRAF 673 Sorafenib BAY 43-9006, BAY 43-9006 tosylate salt, Nexavar Sorafenib 216239 N/A inhibitors RAF, VEGFR2, and PDGFR-beta inhibitors NCT01303341 Advanced solid tumors A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma I 1
BRAF BRAF 673 Vemurafenib PLX4032, RO5185426, Zelboraf Vemurafenib 23252090 N/A inhibitor BRAF kinase inhibitor NCT01596140 B-RAF mutated advanced solid tumors A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer I 1
BRAF BRAF 673 Dabrafenib BRAF inhibitor GSK2118436, GSK2118436, Tafinlar GSK 2118436 44516822 N/A inhibitor BRAF kinase inhibitor NCT01902173 BRAF V600 mutant metastatic cancer Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With the BRAF Inhibitor Dabrafenib in Patients With BRAF Mutant Cancer I 1
RAF BRAF 673 LGX818 Raf Kinase Inhibitor LGX818 N/A N/A N/A inhibitor RAF inhibitor NCT01543698 Solid Tumors Harboring a BRAF V600 Mutation A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors Ib/II 1
c-Met c-Met 4233 EMD 1214063 N/A N/A N/A N/A inhibitor c-Met kinase inhibitor NCT01014936 Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1214063 Under Two Different Regimens in Subjects With Advanced Solid Tumors I 1
c-Met c-Met 4233 AMG 337 N/A N/A N/A N/A inhibitor c-Met inhibitor NCT01253707 Advanced solid tumors A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors I 1
c-Met c-Met 4233 INC280 N/A N/A N/A N/A inhibitor c-Met kinase inhibitor NCT01324479 c-Met dependent advanced solid tumors A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors I 1
c-Met c-Met 4233 Cabozantanib Cabozantinib, Cometriq cabozantinib 25102847 N/A inhibitor RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor NCT01716715 Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER II 1
Caspases CASP3 836 Idronoxil Phenoxodiol phenoxodiol 219100 N/A inhibitor Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor NCT00303888 Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer I/II 1
CD27 CD27 939 CDX-1127 Anti-CD27 Monoclonal Antibody CDX-1127 N/A N/A N/A immunostimulator immunostimulator NCT01460134 Recurrent or refractory ovarian cancer A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors I 1
UNK Cancer Stem Cell antigen CD276 80381 MGA271 mab MGA271 N/A N/A N/A antigen immunological response against cancer antigen NCT01391143 B7-H3 over-expressing adv cancer A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer I 1
CDK1, 2, 3, 4, 7, 9 CDK1 983 BAY 1000394 pan-CDK Inhibitor BAY1000394 N/A N/A N/A inhibitor pan-CDK inhibitor NCT01188252 Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies I 1
CDK1, 2, 5, 9 CDK1 983 Dinaciclib SCH 727965, CDK inhibitor SCH 727965 dinaciclib 46926350 N/A inhibitor CDK inhibitor NCT01676753 Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression I 1
CDK1, 2, 5, 9 CDK1 983 Dinaciclib SCH 727965, CDK inhibitor SCH 727965 dinaciclib 46926350 N/A inhibitor CDK inhibitor NCT01676753 Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression I 1
CDK1, 2, 3, 4, 7, 9 CDK2 1017 BAY 1000394 pan-CDK Inhibitor BAY1000394 N/A N/A N/A inhibitor pan-CDK inhibitor NCT01188252 Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies I 1
CDK1, 2, 5, 9 CDK2 1017 Dinaciclib SCH 727965, CDK inhibitor SCH 727965 dinaciclib 46926350 N/A inhibitor CDK inhibitor NCT01676753 Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression I 1
CDK1, 2, 5, 9 CDK2 1017 Dinaciclib SCH 727965, CDK inhibitor SCH 727965 dinaciclib 46926350 N/A inhibitor CDK inhibitor NCT01676753 Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression I 1
CDK1, 2, 3, 4, 7, 9 CDK3 1018 BAY 1000394 pan-CDK Inhibitor BAY1000394 N/A N/A N/A inhibitor pan-CDK inhibitor NCT01188252 Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies I 1
CDK1, 2, 3, 4, 7, 9 CDK4 1019 BAY 1000394 pan-CDK Inhibitor BAY1000394 N/A N/A N/A inhibitor pan-CDK inhibitor NCT01188252 Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies I 1
CDK4/6 CDK4 1019 LEE011 CDK4/6 Inhibitor LEE011 N/A N/A N/A inhibitor CDK4/6 inhibitor NCT01237236 Advanced cancer A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma I 1
CDK4/6 CDK4 1019 LY2835219 CDK4/6 Dual Inhibitor LY2835219 CS1229 71576678 N/A inhibitor CDK4/6 inhibitor NCT01394016 Advanced Cancer A Phase 1 Study of LY2835219 In Subjects With Advanced Cancer I 1
CDK4/6 CDK4 1019 Palbociblib PD0332991 CID 5330286 5330286 N/A inhibitor CDK4/6 inhibitor NCT01037790 Recurrent Ovarian Cancer Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer II 1
CDK4/6 CDK4 1019 Palbociblib PD0332991 CID 5330286 5330286 N/A inhibitor CDK4/6 inhibitor NCT01536743 Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression II 1
CDK1, 2, 5, 9 CDK5 1020 Dinaciclib SCH 727965, CDK inhibitor SCH 727965 dinaciclib 46926350 N/A inhibitor CDK inhibitor NCT01676753 Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression I 1
CDK1, 2, 5, 9 CDK5 1020 Dinaciclib SCH 727965, CDK inhibitor SCH 727965 dinaciclib 46926350 N/A inhibitor CDK inhibitor NCT01676753 Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression I 1
CDK4/6 CDK6 1021 LEE011 CDK4/6 Inhibitor LEE011 N/A N/A N/A inhibitor CDK4/6 inhibitor NCT01237236 Advanced cancer A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma I 1
CDK4/6 CDK6 1021 LY2835219 CDK4/6 Dual Inhibitor LY2835219 CS1229 71576678 N/A inhibitor CDK4/6 inhibitor NCT01394016 Advanced Cancer A Phase 1 Study of LY2835219 In Subjects With Advanced Cancer I 1
CDK4/6 CDK6 1021 Palbociblib PD0332991 CID 5330286 5330286 N/A inhibitor CDK4/6 inhibitor NCT01037790 Recurrent Ovarian Cancer Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer II 1
CDK4/6 CDK6 1021 Palbociblib PD0332991 CID 5330286 5330286 N/A inhibitor CDK4/6 inhibitor NCT01536743 Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression II 1
CDK1, 2, 3, 4, 7, 9 CDK7 1022 BAY 1000394 pan-CDK Inhibitor BAY1000394 N/A N/A N/A inhibitor pan-CDK inhibitor NCT01188252 Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies I 1
CDK1, 2, 3, 4, 7, 9 CDK9 1025 BAY 1000394 pan-CDK Inhibitor BAY1000394 N/A N/A N/A inhibitor pan-CDK inhibitor NCT01188252 Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies I 1
CDK1, 2, 5, 9 CDK9 1025 Dinaciclib SCH 727965, CDK inhibitor SCH 727965 dinaciclib 46926350 N/A inhibitor CDK inhibitor NCT01676753 Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression I 1
CDK1, 2, 5, 9 CDK9 1025 Dinaciclib SCH 727965, CDK inhibitor SCH 727965 dinaciclib 46926350 N/A inhibitor CDK inhibitor NCT01676753 Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression I 1
FLT3 CFLAR 8837 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
FLIP CFLAR 8837 Idronoxil Phenoxodiol Dehydroequol 219100 N/A inhibitor Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor NCT00303888 Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer I/II 1
FLT3 CFLAR 8837 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
FLT3 CFLAR 8837 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01669798 Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
FLT3 CFLAR 8837 Cabozantanib Cabozantinib, Cometriq Cabozantinib 25102847 N/A inhibitor RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor NCT01716715 Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER II 1
TORC1/2 CRTC1 23373 BEZ235 NYP-BEZ235 NVP-BEZ235 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01343498 Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors I 1
TORC1/2 CRTC1 23373 PF-04691502, PF-05212384 PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587 PKI-587 44516953 N/A inhibitor PI3K/mTOR inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
TORC1/2 CRTC1 23373 DS-7423 N/A N/A N/A N/A inhibitor PI3K/mTOR inhibitor NCT01364844 Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors I 1
TORC1/2 CRTC1 23373 SAR245409 XL765, PI3K/mTOR Dual Kinase Inhibitor XL765 XL765 49867926 N/A inhibitor PI3K/mTOR inhibitor NCT01390818 Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors I 1
TORC1/2 CRTC1 23373 BEZ235 NYP-BEZ235 NVP-BEZ235 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01482156 Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors I 1
TORC1/2 CRTC1 23373 BEZ235 NYP-BEZ235 NVP-BEZ235 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01508104 Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors I 1
TORC1/2 CRTC1 23373 DS-3078a TORC1/2 Kinase Inhibitor DS-3078a N/A N/A N/A inhibitor TORC1/2 kinase inhibitor NCT01588678 Advanced ovarian cancer A Phase 1, Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas I 1
TORC1/2 CRTC1 23373 P7170 PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170 N/A N/A N/A inhibitor PI3K/mTOR/ALK-1/DNA-PK inhibitor NCT01762410 Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors. I 1
TORC1/2 CRTC2 200186 BEZ235 NYP-BEZ235 NVP-BEZ235 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01343498 Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors I 1
TORC1/2 CRTC2 200186 PF-04691502, PF-05212384 PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587 PKI-587 44516953 N/A inhibitor PI3K/mTOR inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
TORC1/2 CRTC2 200186 DS-7423 N/A N/A N/A N/A inhibitor PI3K/mTOR inhibitor NCT01364844 Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors I 1
TORC1/2 CRTC2 200186 SAR245409 XL765, PI3K/mTOR Dual Kinase Inhibitor XL765 XL765 49867926 N/A inhibitor PI3K/mTOR inhibitor NCT01390818 Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors I 1
TORC1/2 CRTC2 200186 BEZ235 NYP-BEZ235 NVP-BEZ235 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01482156 Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors I 1
TORC1/2 CRTC2 200186 BEZ235 NYP-BEZ235 NVP-BEZ235 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01508104 Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors I 1
TORC1/2 CRTC2 200186 DS-3078a TORC1/2 Kinase Inhibitor DS-3078a N/A N/A N/A inhibitor TORC1/2 kinase inhibitor NCT01588678 Advanced ovarian cancer A Phase 1, Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas I 1
TORC1/2 CRTC2 200186 P7170 PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170 N/A N/A N/A inhibitor PI3K/mTOR/ALK-1/DNA-PK inhibitor NCT01762410 Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors. I 1
CSFR1 CSF1R 1436 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
CTLA-4 CTLA-4 1493 Ipilumumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Ipilimumab N/A 131273201 antagonist CTLA-4 antagonist NCT01611558 Platinum-sensitive recurrent ovarian cancer A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy Following Completion of Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects With Residual Measurable Disease II 1
Dihydrofolate reductase (DHFR) DHFR 1719 Pemetrexed Alimta, Pemetrexed disodium pemetrexed 446556 N/A inhibitor DHFR and Thymidylate synthase inhibitor NCT01172028 Advanced, recurrent solid tumor Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors I 1
Dihydrofolate reductase (DHFR) DHFR 1719 Pemetrexed Alimta, Pemetrexed disodium pemetrexed 446556 N/A inhibitor DHFR and Thymidylate synthase inhibitor NCT01567384 Advanced Cancer A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies I 1
Dihydrofolate reductase (DHFR) DHFR 1719 Pralatrexate Folotyn, PDX Pralatrexate 148121 N/A inhibitor RFC-1 targeted DHFR inhibitor NCT01188876 Platinum sensitive relapsed ovarian cancer Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer I/II 1
Dihydrofolate reductase (DHFR) DHFR 1719 Pemetrexed Alimta, Pemetrexed disodium pemetrexed 446556 N/A inhibitor DHFR and Thymidylate synthase inhibitor NCT01001910 Platinum sensitive relapsed ovarian cancer Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer II 1
EGFR EGFR 1956 Lapatinib lapatinib ditosylate, Tykerb Lapatinib 208908 N/A inhibitor HER2 and EGFR kinase inhibitor NCT00313599 Advanced solid cancers A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane in Patients With Advanced Solid Tumors I 1
EGFR EGFR 1956 Panitumumab ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, Vectibix AKOS004227608 50070211 N/A inhibitor EGFR inhibitor NCT00610948 Advanced solid tumors A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies I 1
EGFR EGFR 1956 Erlotinib Tarceva Erlotinib 176870 N/A inhibitor EGFR inhibitor NCT00770263 Advanced solid tumors Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies I 1
EGFR EGFR 1956 Lapatinib lapatinib ditosylate, Tykerb Lapatinib 208908 N/A inhibitor HER2 and EGFR kinase inhibitor NCT01245205 Advanced Solid Tumors A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer I 1
EGFR EGFR 1956 Vandetanib AZD6474, Zactima, ZD6474 Vandetanib 3081361 N/A inhibitor VEGFR, EGFR, and RET inhibitor NCT01582191 Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer I 1
EGFR EGFR 1956 Panitumumab ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, Vectibix AKOS004227608 50070211 N/A inhibitor EGFR inhibitor NCT01296035 Metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer. II 1
EphA2 EPHA2 1969 siRNA-EphA2-DOPC N/A N/A N/A N/A inhibitor EphA2 inhibitor NCT01591356 Advanced ovarian cancer EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial I 1
HER2 ERBB2 2064 Trastuzumab Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin Trastuzumab N/A 50067185 antagonist HER2 antagonist NCT01235897 Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab Ib 1
HER2 ERBB3 2064 MGAH22 anti-HER2 mAb MGAH22, anti-HER2/c-erbB2 monoclonal antibody MGAH22 N/A 160698529 antagonist HER2 antagonist NCT01148849 HER2 positive recurrent carcinoma A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available I 1
ErbB3/HER3 ERBB3 2065 MM-121 SAR256212 CHEMBL2109402 N/A 160698530 inhibitor ErbB3/Her3 inhibitor NCT01209195 Locally advanced/metastatic or recurrent epithelial ovarian cancer A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers I 1
ErbB3/HER3 ERBB3 2065 MM-121 SAR256212 CHEMBL2109402 N/A 160698530 inhibitor ErbB3/Her3 inhibitor NCT01436565 Advanced Cancer A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers I 1
HER2 ERBB4 2064 Pb-TCMC-Trastuzumab N/A N/A N/A N/A radioimmunotherapy HER2-targeted radioimmunotherapy NCT01384253 HER2+ recurrent ovarian cancer Safety Study of Pb-TCMC-Trastuzumab Radio Immunotherapy I 1
HER2 ERBB5 2064 Lapatinib lapatinib ditosylate, Tykerb Lapatinib 208908 208908 inhibitor HER2 and EGFR kinase inhibitor NCT00313599 Advanced solid cancers A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane in Patients With Advanced Solid Tumors I 1
HER2 ERBB6 2064 Lapatinib lapatinib ditosylate, Tykerb Lapatinib 208908 208908 inhibitor HER2 and EGFR kinase inhibitor NCT01245205 Advanced Solid Tumors A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer I 1
ER ESR1 2099 Endoxifen z-Endoxifen Endoxifen 10090750 N/A antagonist ER antagonist NCT01273168 Ovarian cancer did not respond to conventional treatment Endoxifen in Adults With Hormone Receptor-Positive Solid Tumors I 1
Folate receptor 1 ESR1 2099 IMGN853 Anti-FOLR1-mab Maytansinoid Conjugate, M9346A-sulfo-SPDB-DM4 N/A N/A N/A stabilizer FOLR1-targeted microtubule stabilizer NCT01609556 Advanced ovarian cancer A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors I 1
Folate receptor 1 ESR1 2099 Vintafolide EC145, Folate-Vinca Alkaloid Conjugate EC145, MK-8109 EC145 71301286 N/A inhibitor Folate-targeted tubulin inhibitor NCT01688791 Advanced Cancer A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Combinations in Adult Subjects With Advanced Cancers I 1
ER ESR1 2099 Tamoxifen N/A tamoxifen 2733526 N/A antagonist ER antagonist NCT01685255 Biochemical recurrent epithelial ovarian cancer A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY II 1
Folate receptor 1 ESR1 2099 Vintafolide EC145, Folate-Vinca Alkaloid Conjugate EC145, MK-8109 EC145 71301286 N/A inhibitor Folate-targeted tubulin inhibitor NCT01170650 primary or secondary platinum-resistant ovarian cancer Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) III 1
FGFR FGFR1 2260 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
FGFR FGFR1 2260 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
FGFR FGFR1 2260 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01669798 Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
FGFR FGFR1 2260 ENMD-2076 N/A ENMD-2076 16041424 N/A inhibitor Aurora A and VEGFR/FGFR kinase inhibitor NCT01914510 Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas II 1
FGFR FGFR2 2263 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
FGFR FGFR2 2263 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
FGFR FGFR2 2263 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01669798 Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
FGFR FGFR2 2263 ENMD-2076 N/A ENMD-2076 16041424 N/A inhibitor Aurora A and VEGFR/FGFR kinase inhibitor NCT01914510 Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas II 1
FGFR FGFR3 2261 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
FGFR FGFR3 2261 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
FGFR FGFR3 2261 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01669798 Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
FGFR FGFR3 2261 ENMD-2076 N/A ENMD-2076 16041424 N/A inhibitor Aurora A and VEGFR/FGFR kinase inhibitor NCT01914510 Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas II 1
FGFR FGFR4 2264 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
FGFR FGFR4 2264 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
FGFR FGFR4 2264 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01669798 Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
FGFR FGFR4 2264 ENMD-2076 N/A ENMD-2076 16041424 N/A inhibitor Aurora A and VEGFR/FGFR kinase inhibitor NCT01914510 Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas II 1
FKBP-12 FKBP1A 2280 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT00610948 Advanced solid tumors A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies I 1
FKBP-12 FKBP1A 2280 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01087554 Advanced solid tumors A Phase I Trial of Sirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer I 1
FKBP-12 FKBP1A 2280 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01122199 Metastatic solid tumor refractory to standard therapies Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors I 1
FKBP-12 FKBP1A 2280 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01281514 Platinum-sensitive ovarian cancer at first relapse PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE I 1
FKBP-12 FKBP1A 2280 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01482156 Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors I 1
FKBP-12 FKBP1A 2280 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01582191 Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer I 1
FKBP-12 FKBP1A 2280 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01596140 B-RAF mutated advanced solid tumors A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer I 1
FKBP-12 FKBP1A 2280 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01624766 Advanced cancers A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies I 1
FKBP-12 FKBP1A 2280 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01031381 Recurrent epithelial ovarian carcinoma Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV) II 1
VEGFR2 FLK1 3791 Sorafenib BAY 43-9006, BAY 43-9006 tosylate salt, Nexavar Sorafenib 216239 N/A inhibitors RAF, VEGFR2, and PDGFR-beta inhibitors NCT01303341 Advanced solid tumors A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma I 1
VEGFR1, 2, 3 FLK1 3791 Cediranib AZD2171, Cediranib maleate, Recentin Cediranib 9933475 N/A inhibitor VEGFR inhibitor NCT01364051 Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies I 1
VEGFR1, 2, 3 FLK1 3791 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01438554 Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer I 1
VEGFR FLK1 3791 Vandetanib AZD6474, Zactima, ZD6474 Vandetanib 3081361 N/A inhibitor VEGFR, EGFR, and RET inhibitor NCT01582191 Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer I 1
VEGFR1, 2, 3 FLK1 3791 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01639911 Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
VEGFR1, 2, 3 FLK1 3791 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01639911 Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
VEGFR FLK1 3791 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
VEGFR FLK1 3791 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
VEGFR1, 2, 3 FLK1 3791 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01610206 Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
VEGFR FLK1 3791 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01669798 Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
VEGFR2 FLK1 3791 Cabozantanib Cabozantinib, Cometriq Cabozantinib 25102847 N/A inhibitor RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor NCT01716715 Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER II 1
VEGFR1, 2, 3 FLK1 3791 Tivozanib AV-951 tivozanib 9911830 N/A inhibitor VEGFR inhibitor NCT01853644 Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer II 1
VEGFR FLK1 3791 ENMD-2076 N/A ENMD 2076 16041424 N/A inhibitor Aurora A and VEGFR/FGFR kinase inhibitor NCT01914510 Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas II 1
VEGFR1, 2, 3 FLT1 2321 Cediranib AZD2171, Cediranib maleate, Recentin Cediranib 9933475 N/A inhibitor VEGFR inhibitor NCT01364051 Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies I 1
VEGFR1, 2, 3 FLT1 2321 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01438554 Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer I 1
VEGFR FLT1 2321 Vandetanib AZD6474, Zactima, ZD6474 Vandetanib 3081361 N/A inhibitor VEGFR, EGFR, and RET inhibitor NCT01582191 Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer I 1
VEGFR1, 2, 3 FLT1 2321 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01639911 Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
VEGFR1, 2, 3 FLT1 2321 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01639911 Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
VEGFR FLT1 2321 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
VEGFR FLT1 2321 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
VEGFR1, 2, 3 FLT1 2321 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01610206 Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
VEGFR FLT1 2321 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01669798 Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
VEGFR1, 2, 3 FLT1 2321 Tivozanib AV-951 tivozanib 9911830 N/A inhibitor VEGFR inhibitor NCT01853644 Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer II 1
VEGFR FLT1 2321 ENMD-2076 N/A ENMD 2076 16041424 N/A inhibitor Aurora A and VEGFR/FGFR kinase inhibitor NCT01914510 Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas II 1
VEGFR1, 2, 3 FLT4 2324 Cediranib AZD2171, Cediranib maleate, Recentin Cediranib 9933475 N/A inhibitor VEGFR inhibitor NCT01364051 Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies I 1
VEGFR1, 2, 3 FLT4 2324 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01438554 Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer I 1
VEGFR FLT4 2324 Vandetanib AZD6474, Zactima, ZD6474 Vandetanib 3081361 N/A inhibitor VEGFR, EGFR, and RET inhibitor NCT01582191 Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer I 1
VEGFR1, 2, 3 FLT4 2324 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01639911 Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
VEGFR1, 2, 3 FLT4 2324 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01639911 Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
VEGFR FLT4 2324 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
VEGFR FLT4 2324 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
VEGFR1, 2, 3 FLT4 2324 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01610206 Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
VEGFR FLT4 2324 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01669798 Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
VEGFR1, 2, 3 FLT4 2324 Tivozanib AV-951 tivozanib 9911830 N/A inhibitor VEGFR inhibitor NCT01853644 Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer II 1
VEGFR FLT4 2324 ENMD-2076 N/A ENMD 2076 16041424 N/A inhibitor Aurora A and VEGFR/FGFR kinase inhibitor NCT01914510 Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas II 1
PSMA FOLH1 2346 PSMA-targeted Docetaxel Nanoparticles BIND-014 BIND-014 Docetaxel 148124 N/A inhibitor Tubulin inhibitor NCT01300533 Advanced ovarian cancer not responsive to standard therapies A Phase I, Open Label , Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 Given by IV Infusion to Patients With Advanced or Metastatic Cancer I 1
ALK1 ligands (TGFbeta family) GDF2 2658 Dalantercept ACE-041, ALK1-Fc Fusion Protein ACE-041 Dalantercept N/A 160693095 inhibitor ALK1 inhibitor NCT01720173 Recurrent epithelial ovarian cancer A Phase II Evaluation of Dalantercept (NSC #75172, IND #116598), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
HDAC HDAC10 9735 Vorinostat SAHA, SuberoylaN/Aide hydroxamic acid, Zolinza Vorinostat 5311 N/A inhibitor HDAC inhibitor NCT01087554 Advanced solid tumors A Phase I Trial of Sirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer I 1
HDAC HDAC11 9736 Vorinostat SAHA, SuberoylaN/Aide hydroxamic acid, Zolinza Vorinostat 5311 N/A inhibitor HDAC inhibitor NCT01266057 Advanced or metastatic cancers A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies I 1
HDAC HDAC9 9734 Vorinostat SAHA, SuberoylaN/Aide hydroxamic acid, Zolinza Vorinostat 5311 N/A inhibitor HDAC inhibitor NCT00976183 Stage III/IV ovarian cancer cancer, not have received chemotherapy yet Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma I/II 1
HIF1-alpha HIF1A 3091 CRLX101 camptothecin-polymer conjugate IT-101, cyclodextrin-based polymer-camptothecin CRLX101, IT-101 N/A N/A N/A HIF-1alpha dual inhibitor of topoisomerase 1 and HIF-1alpha NCT01652079 Recurrent epithelial cancer A Phase II, 2-stage Trial of CRLX101-202 in Recurrent Ovarian, Tubal and Peritoneal Cancer II 1
HMG-CoA reductase HMGCR 3156 Lovastatin Mevacor, Mevinolin, Monacolin-K lovastatin 53232 N/A inhibitor HMG-CoA reductase inhibitor NCT00585052 Platinum-refractory or -resistant ovarian cancer A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer II 1
3-dioxygenase IDO1 3620 INCB024360 3-dioxygenase Inhibitor INCB024360, IDO1 Inhibitor INCB024360, Indoleamine-2 N/A N/A N/A inhibitor 3-dioxygenase (INDO) inhibitor NCT01685255 Biochemical recurrent epithelial ovarian cancer A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY II 1
IGF1R IGF1R 3480 AMG 479 N/A N/A N/A N/A inhibitor IGF1R inhibitor NCT01122199 Metastatic solid tumor refractory to standard therapies Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors I 1
IGF1R IGF1R 3480 Linsitinib OSI-906 Linsitinib 11640390 N/A inhibitor IGF1R inhibitor NCT01567384 Advanced Cancer A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies I 1
IGF1R IGF1R 3480 AMG 479 N/A N/A N/A N/A inhibitor IGF1R inhibitor NCT01708161 Advanced ovarian cancer with PIK3CA mutation A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors I/II 1
IL-12 IL-12A 3592 EGEN-001 phIL-12-005/PPC CID 446414 446414 N/A unknown N/A NCT01489371 Recurrent epithelial ovarian cancer A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With doxil (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer I 1
IL-12 IL-12B 3593 EGEN-001 phIL-12-005/PPC CID 446414 446414 N/A unknown N/A NCT01489371 Recurrent epithelial ovarian cancer A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With doxil (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer I 1
IL-1R IL-1R1 3554 Anakinra N/A Anakinra N/A 53790816 antagonist IL-1 receptor antagonist NCT01624766 Advanced cancers A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies I 1
IL-1R IL-1R2 7850 Anakinra N/A Anakinra N/A 53790816 antagonist IL-1 receptor antagonist NCT01624766 Advanced cancers A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies I 1
indoleamine 2 INDO2 169355 INCB024360 3-dioxygenase Inhibitor INCB024360, IDO1 Inhibitor INCB024360, Indoleamine-2 N/A N/A N/A inihibitor 3-dioxygenase (INDO) inhibitor, indoleamine 2 NCT01685255 Biochemical recurrent epithelial ovarian cancer A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY II 1
RTK KDR 3791 Cabozantanib Cabozantinib, Cometriq Cabozantinib 25102847 N/A inhibitor RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor NCT01716715 Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER II 1
KIR (killer-cell Ig-like receptors) KIR3DL3 115653 BMS-986015 Anti-KIR mab IPH2102, IPH2102 N/A N/A N/A activator NK cell activator NCT01714739 Advanced ovarian cancer A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination With Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors I 1
cKIT KIT 3815 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
p38 MAPK (MAPK14) MAPK14 1432 LY2228820 N/A LY2228820 11570805 N/A inhibitor p38 mitogen-activated protein kinase (MAPKs) inhib NCT01663857 Platinum sensitive ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer I/II 1
MEK MEK1 5604 GDC-0973 XL518 XL518 16222096 N/A inhibitor MEK inhibitor NCT00996892 Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors i 1
MEK MEK1 5604 Trametinib GSK1120212, JTP-74057, MEK Inhibitor GSK1120212 Trametinib 11707110 N/A inhibitor MEK 1/2 inhibitor NCT01138085 Advanced Solid Tumors A Phase I Dose Escalation Open-Label Safety and Pharmacokinetic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 in Subjects With Solid Tumors (Part 1) and in Subjects With Pancreatic Cancer, Endometrial Cancer or Colorectal Cancer (Part 2) I 1
MEK MEK1 5604 Trametinib GSK1120212, JTP-74057, MEK Inhibitor GSK1120212 Trametinib 11707110 N/A inhibitor MEK 1/2 inhibitor NCT01248858 Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. I 1
MEK MEK1 5604 MEK162 ARRY-162, ARRY-438162, MEK inhibitor MEK162 MEK162 10288191 N/A inhibitor MEK inhibitor NCT01363232 NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors I 1
MEK MEK1 5604 Selumetinib ARRY-142886, AZD6244 Selumetinib 10127622 N/A inhibitor MEK inhibitor NCT01364051 Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies I 1
MEK MEK1 5604 Pimasertib AS703026, EMD 1036239, MSC1936369B Pimasertib 44187362 N/A inhibitor MEK1/2 inhibitor NCT01390818 Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors I 1
MEK MEK1 5604 Trametinib GSK1120212, JTP-74057, MEK Inhibitor GSK1120212 Trametinib 11707110 N/A inhibitor MEK 1/2 inhibitor NCT01438554 Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer I 1
MEK MEK1 5604 MSC2015103B N/A N/A N/A N/A inhibitor MEK inhibitor NCT01453387 Advanced Cancer MSC2015103B in Solid Tumors I 1
MEK MEK1 5604 WX-554 N/A N/A N/A N/A inhibitor MEK inhibitor NCT01581060 Advanced solid tumors A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours I 1
MEK MEK1 5604 MEK162 ARRY-162, ARRY-438162, MEK inhibitor MEK162 MEK162 10288191 N/A inhibitor MEK inhibitor NCT01649336 Platinum resistant epithelial ovarian cancer A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer I 1
MEK MEK1 5604 Rafametinib BAY86-9766, RDEA119 BAY 869766 44182295 N/A inhibitor MEK inhibitor NCT01392521 Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer Ib 1
MEK MEK1 5604 MEK162 ARRY-162, ARRY-438162, MEK inhibitor MEK162 MEK162 10288191 N/A inhibitor MEK inhibitor NCT01449058 Advanced BRAF or KRAS mutant cancers A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Ib 1
MEK MEK1 5604 GDC-0973 XL518 XL518 16222096 N/A inhibitor MEK inhibitor NCT01562275 Locally advanced or metastatic solid tumors A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors Ib 1
MEK MEK1 5604 TAK-733 MEK Inhibitor TAK-733 TAK-733 24963252 N/A inhibitor MEK inhibitor NCT01613261 Advanced Solid Tumors A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies Ib 1
MEK MEK1 5604 MEK162 ARRY-162, ARRY-438162, MEK inhibitor MEK162 MEK164 10288191 N/A inhibitor MEK inhibitor NCT01543698 Solid Tumors Harboring a BRAF V600 Mutation A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors Ib/II 1
MEK MEK1 5604 MEK162 ARRY-162, ARRY-438162, MEK inhibitor MEK162 MEK162 10288191 N/A inhibitor MEK inhibitor NCT01849874 Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer III 1
MEK MEK2 5605 GDC-0973 XL518 XL518 16222096 N/A inhibitor MEK inhibitor NCT00996892 Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors i 1
MEK MEK2 5605 Trametinib GSK1120212, JTP-74057, MEK Inhibitor GSK1120212 Trametinib 11707110 N/A inhibitor MEK 1/2 inhibitor NCT01138085 Advanced Solid Tumors A Phase I Dose Escalation Open-Label Safety and Pharmacokinetic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 in Subjects With Solid Tumors (Part 1) and in Subjects With Pancreatic Cancer, Endometrial Cancer or Colorectal Cancer (Part 2) I 1
MEK MEK2 5605 Trametinib GSK1120212, JTP-74057, MEK Inhibitor GSK1120212 Trametinib 11707110 N/A inhibitor MEK 1/2 inhibitor NCT01248858 Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. I 1
MEK MEK2 5605 MEK162 ARRY-162, ARRY-438162, MEK inhibitor MEK162 MEK162 10288191 N/A inhibitor MEK inhibitor NCT01363232 NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors I 1
MEK MEK2 5605 Selumetinib ARRY-142886, AZD6244 Selumetinib 10127622 N/A inhibitor MEK inhibitor NCT01364051 Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies I 1
MEK MEK2 5605 Pimasertib AS703026, EMD 1036239, MSC1936369B Pimasertib 44187362 N/A inhibitor MEK1/2 inhibitor NCT01390818 Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors I 1
MEK MEK2 5605 Trametinib GSK1120212, JTP-74057, MEK Inhibitor GSK1120212 Trametinib 11707110 N/A inhibitor MEK 1/2 inhibitor NCT01438554 Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer I 1
MEK MEK2 5605 MSC2015103B N/A N/A N/A N/A inhibitor MEK inhibitor NCT01453387 Advanced Cancer MSC2015103B in Solid Tumors I 1
MEK MEK2 5605 WX-554 N/A N/A N/A N/A inhibitor MEK inhibitor NCT01581060 Advanced solid tumors A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours I 1
MEK MEK2 5605 MEK162 ARRY-162, ARRY-438162, MEK inhibitor MEK162 MEK162 10288191 N/A inhibitor MEK inhibitor NCT01649336 Platinum resistant epithelial ovarian cancer A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer I 1
MEK MEK2 5605 Rafametinib BAY86-9766, RDEA119 BAY 869766 44182295 N/A inhibitor MEK inhibitor NCT01392521 Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer Ib 1
MEK MEK2 5605 MEK162 ARRY-162, ARRY-438162, MEK inhibitor MEK162 MEK162 10288191 N/A inhibitor MEK inhibitor NCT01449058 Advanced BRAF or KRAS mutant cancers A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Ib 1
MEK MEK2 5605 GDC-0973 XL518 XL518 16222096 N/A inhibitor MEK inhibitor NCT01562275 Locally advanced or metastatic solid tumors A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors Ib 1
MEK MEK2 5605 TAK-733 MEK Inhibitor TAK-733 TAK-733 24963252 N/A inhibitor MEK inhibitor NCT01613261 Advanced Solid Tumors A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies Ib 1
MEK MEK2 5605 MEK162 ARRY-162, ARRY-438162, MEK inhibitor MEK162 MEK165 10288191 N/A inhibitor MEK inhibitor NCT01543698 Solid Tumors Harboring a BRAF V600 Mutation A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors Ib/II 1
MEK MEK2 5605 MEK162 ARRY-162, ARRY-438162, MEK inhibitor MEK162 MEK163 10288191 N/A inhibitor MEK inhibitor NCT01849874 Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer III 1
RTK MET 4233 Cabozantanib Cabozantinib, Cometriq Cabozantinib 25102847 N/A inhibitor RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor NCT01716715 Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER II 1
mTOR MTOR 2475 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT00610948 Advanced solid tumors A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies I 1
mTOR MTOR 2475 Temsirolimus CCI-779, Torisel Temsirolimus 6918289 N/A inhibitor mTOR inhibitor NCT00770263 Advanced solid tumors Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies I 1
mTOR MTOR 2475 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01087554 Advanced solid tumors A Phase I Trial of Sirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer I 1
mTOR MTOR 2475 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01122199 Metastatic solid tumor refractory to standard therapies Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors I 1
mTOR MTOR 2475 Ridaforolimus Deforolimus Deforolimus 11520894 N/A inhibitor mTOR inhibitor NCT01256268 Metastatic or Recurrent Ovarian Cancer elegible for carbo-taxol treatment Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids I 1
mTOR MTOR 2475 Rapamycin Rapamune, Sirolimus Sirolimus 5284616 N/A inhibitor mTOR inhibitor NCT01266057 Advanced or metastatic cancers A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies I 1
mTOR MTOR 2475 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01281514 Platinum-sensitive ovarian cancer at first relapse PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE I 1
mTOR MTOR 2475 Ridaforolimus Deforolimus Deforolimus 11520894 N/A inhibitor mTOR inhibitor NCT01295632 Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer I 1
mTOR MTOR 2475 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01482156 Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors I 1
mTOR MTOR 2475 Temsirolimus CCI-779, Torisel Temsirolimus 6918289 N/A inhibitor mTOR inhibitor NCT01529593 Advanced cancers Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers I 1
mTOR MTOR 2475 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01582191 Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer I 1
mTOR MTOR 2475 Everolimus, Temsirolimus Afinitor, CCI-779, Certican, RAD001, Torisel, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01596140 B-RAF mutated advanced solid tumors A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer I 1
mTOR MTOR 2475 Everolimus, Temsirolimus Afinitor, CCI-779, Certican, RAD001, Torisel, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01596140 B-RAF mutated advanced solid tumors A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer I 1
mTOR MTOR 2475 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01624766 Advanced cancers A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies I 1
mTOR MTOR 2475 Temsirolimus CCI-779, Torisel Temsirolimus 6918289 N/A inhibitor mTOR inhibitor NCT00982631 Advanced or Recurrent Ovarian Cancer A Phase Ib Study of Combination of Temsirolimus (Torisel) and Pegylated Liposomal Doxorubicin (PLD, Doxil/ Caelyx) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer Ib 1
mTOR MTOR 2475 Temsirolimus CCI-779, Torisel Temsirolimus 6918289 N/A inhibitor mTOR inhibitor NCT01010126 Locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor. Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor II 1
mTOR MTOR 2475 Everolimus Afinitor, Certican, RAD001, Zortress Everolimus 6442177 N/A inhibitor mTOR inhibitor NCT01031381 Recurrent epithelial ovarian carcinoma Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV) II 1
mTOR MTOR 2475 Temsirolimus CCI-779, Torisel Temsirolimus 6918289 N/A inhibitor mTOR inhibitor NCT01196429 Newly diagnosed stage III or stage IV clear cell ovarian cancer. Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer II 1
CA125 MUC16 94025 DMUC5754A N/A N/A N/A N/A unknown N/A NCT01335958 Platinum-resistant ovarian cancer A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer I 1
CA125 MUC16 94025 Oregovomab B43.13, Monoclonal Antibody B43.13, OvaRex N/A N/A N/A antigen immunological response against cancer antigen NCT01616303 Newly diagnosed advanced ovarian cancer Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma II 1
FGF N/A N/A Lenalidomide CC-5013, IMID-1, Revlimid Lenalidomide 216326 N/A Anti-angiogenic. Anti-angiogenic. NCT01146795 Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer 0 0 Not sure what to do here, there are a large number of VGFs... Maybe drop these...
Tubulin N/A N/A Paclitaxel Albumin-Stabilized Nanoparticle Formulation ABI-007, Abraxane, nab-paclitaxel Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00313599 Advanced solid cancers A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane in Patients With Advanced Solid Tumors I 0
Tubulin N/A N/A Docetaxel Taxotere docetaxel 148124 N/A inhibitor Tubulin and VEGF inhibitor NCT00692900 Platinum-resistant or -sensitive ovarian epithelial cancer Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer I 0
Tubulin N/A N/A Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation ABI-007, Abraxane, Anzatax, Asotax, Bristaxol, nab-paclitaxel, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00825201 Advanced cancer of the peritoneal cavity. Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity I 0
Tubulin N/A N/A Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation ABI-007, Abraxane, Anzatax, Asotax, Bristaxol, nab-paclitaxel, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00825201 Advanced cancer of the peritoneal cavity. Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity I 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00989651 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer I 0
20S Proteasome N/A N/A Bortezomib PS-341, Velcade Bortezomib 387447 N/A inhibitor Proteosome and NF-kappaB inhibitor NCT01074411 Persistent or recurrent ovarian epithelial cancer Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer I 0 20S proteasome is not really a gene ... exclude this entry
Tubulin N/A N/A Docetaxel Taxotere docetaxel 148124 N/A inhibitor Tubulin and VEGF inhibitor NCT01094288 Advanced Solid Tumors A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen I 0
Tubulin N/A N/A Vinorelbine ditartrate Biovelbin, Eunades, Navelbine, Navelbine ditartrate, NVB, Vinorelbine tartrate, VNB Navelbin 60779 N/A inhibitor Tubulin inhibitor NCT01104259 BRCA1/2 hereditary ovarian cancer Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer I 0
Tubulin N/A N/A Docetaxel Taxotere docetaxel 148124 N/A inhibitor Tubulin and VEGF inhibitor NCT01110486 Advanced solid tumors A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors I 0
Tubulin N/A N/A Docetaxel Taxotere docetaxel 148124 N/A inhibitor Tubulin and VEGF inhibitor NCT01172028 Advanced, recurrent solid tumor Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors I 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01209195 Locally advanced/metastatic or recurrent epithelial ovarian cancer A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers I 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01248949 Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors I 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01256268 Metastatic or Recurrent Ovarian Cancer elegible for carbo-taxol treatment Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids I 0
lysosome N/A N/A Hydroxychloroquine PlaqueN/A hydroxychloroquine 3652 N/A inhibitor Autophagy inhibitor NCT01266057 Advanced or metastatic cancers A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies I 0
Tubulin N/A N/A PSMA-targeted Docetaxel Nanoparticles BIND-014 BIND-014 N/A N/A N/A inhibitor Tubulin inhibitor NCT01300533 Advanced ovarian cancer not responsive to standard therapies A Phase I, Open Label , Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 Given by IV Infusion to Patients With Advanced or Metastatic Cancer I 0
FGF N/A N/A Lenalidomide CC-5013, IMID-1, Revlimid Lenalidomide 216326 N/A Anti-angiogenic. Anti-angiogenic. NCT01352962 Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors I 0 Not sure what to do here, there are a large number of VGFs... Maybe drop these... (drug is broad acting in anti-angiogenesis)
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01366144 Recurrent or stage IV ovarian cancer An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors I 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01411410 Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy I 0
lysosome N/A N/A Hydroxychloroquine PlaqueN/A hydroxychloroquine 3652 N/A inhibitor Autophagy inhibitor NCT01480154 Advanced Solid Tumors A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis I 0 Drug
Tubulin N/A N/A IMGN853 Anti-FOLR1-mab Maytansinoid Conjugate, M9346A-sulfo-SPDB-DM4 N/A N/A N/A stabilizer FOLR1-targeted microtubule stabilizer NCT01609556 Advanced ovarian cancer A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors I 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01649336 Platinum resistant epithelial ovarian cancer A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer I 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01676753 Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression I 0
Tubulin N/A N/A Paclitaxel, Vintafolide Anzatax, Asotax, Bristaxol, EC145, Folate-Vinca Alkaloid Conjugate EC145, MK-8109, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Folate-targeted tubulin inhibitor, Tubulin and Bcl2 inhibitor NCT01688791 Advanced Cancer A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Combinations in Adult Subjects With Advanced Cancers I 0
Tubulin N/A N/A Paclitaxel, Vintafolide Anzatax, Asotax, Bristaxol, EC145, Folate-Vinca Alkaloid Conjugate EC145, MK-8109, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Folate-targeted tubulin inhibitor, Tubulin and Bcl2 inhibitor NCT01688791 Advanced Cancer A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Combinations in Adult Subjects With Advanced Cancers I 0
Tubulin N/A N/A ATI1123 Taxotere N/A N/A N/A inhibitor Tubulin inhibitor NCT01715168 Recurrent ovarian cancer A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy I 0
DNA-PK N/A N/A P7170 PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170 N/A N/A N/A inhibitor PI3K/mTOR/ALK-1/DNA-PK inhibitor NCT01762410 Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors. I 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01778803 Adv or refractory ovarian cancer A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer I 0
Tubulin N/A N/A ATI1123 Taxotere N/A N/A N/A inhibitor Tubulin inhibitor NCT01815294 Advanced solid tumors A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer. I 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01831089 Advanced solid tumors Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors I 0
Tubulin N/A N/A Docetaxel Taxotere docetaxel 148124 N/A inhibitor Tubulin and VEGF inhibitor NCT00303888 Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer I/II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00976183 Stage III/IV ovarian cancer cancer, not have received chemotherapy yet Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma I/II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01091428 Recurrent epithelial ovarian carcinoma MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer I/II 0
Tubulin N/A N/A BNC105P N/A BNC105p 16678086 N/A inhibitor microtubule polymerization inhibitor NCT01624493 Relapsed ovarian cancer, platinum sensitive Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse I/II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01650376 Relapsed ovarian cancer Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients I/II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01653912 Recurrent platinum-resistant ovarian cancer An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer I/II 0
DNA methyltransferase N/A N/A SGI-110 DNA methyltransferase inhibitor SGI-110 UNII-0RB89YH367 71587873 N/A inhibitor DNA methyltransferase inhibitor NCT01696032 Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer I/II 0 Drug is a hypomethylating agent, no targetting of specific gene
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01696032 Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer I/II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01711970 Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Mllerian Cancer I/II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01235897 Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab Ib 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00585052 Platinum-refractory or -resistant ovarian cancer A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01097746 Newly diagnosed stage III, IV ovarian epithelial cancer First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01196429 Newly diagnosed stage III or stage IV clear cell ovarian cancer. Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer II 0
Tubulin N/A N/A Fosbretabulin Combretastatin A-4 Phosphate, fosbretabulin tromethamine, Zybrestat Fosbretabulin 5351387 N/A inhibitor tubulin polymerization inhibitor NCT01305213 Platinum sensitive recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01357161 Platinum-sensitive p53 mutant ovarian cancer A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01616303 Newly diagnosed advanced ovarian cancer Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma II 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01716715 Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER II 0
Tubulin N/A N/A Paclitaxel, Paclitaxel Poliglumex Anzatax, Asotax, Bristaxol, paclitaxel-polyglutamate polymer, polyglutamate paclitaxel, polyglutamic acid paclitaxel, Poly-L-Glutamic acid-Paclitaxel Conjugate, Praxel, Taxol, Taxol Konzentrat, TXL, Xyotax Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00108745 Stage III-IV ovarian epithelial cancer Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer III 0
Tubulin N/A N/A Paclitaxel, Paclitaxel Poliglumex Anzatax, Asotax, Bristaxol, paclitaxel-polyglutamate polymer, polyglutamate paclitaxel, polyglutamic acid paclitaxel, Poly-L-Glutamic acid-Paclitaxel Conjugate, Praxel, Taxol, Taxol Konzentrat, TXL, Xyotax Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00108745 Stage III-IV ovarian epithelial cancer Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer III 0
Tubulin N/A N/A Docetaxel, Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Taxotere, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor, Tubulin and VEGF inhibitor NCT00565851 Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer III 0
Tubulin N/A N/A Docetaxel, Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Taxotere, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor, Tubulin and VEGF inhibitor NCT00565851 Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer III 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT00954174 Persistent or recurrent ovarian cancer Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer III 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01081262 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer III 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01167712 Stage III, IV ovarian epithelial cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer III 0
Tubulin N/A N/A Vintafolide EC145, Folate-Vinca Alkaloid Conjugate EC145, MK-8109 Paclitaxel N/A 162109041 inhibitor Folate-targeted tubulin inhibitor NCT01170650 primary or secondary platinum-resistant ovarian cancer Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) III 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01239732 Newly diagnosed advanced ovarian cncer Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma III 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01493505 Newly diagnosed stage III-IV ovarian epithelial cancer A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers III 0
Tubulin N/A N/A Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Paclitaxel 36314 N/A inhibitor Tubulin and Bcl2 inhibitor NCT01849874 Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer III 0
Beta-adrenergic receptors N/A N/A propanolol Inderal, InnoPranXL Propranolol 4946 N/A blocker Beta blocker NCT01308944 diagnosed ovarian, fallopian tube, or primary peritoneal cancer Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients N/A 0
Beta-adrenergic receptors N/A N/A propanolol Inderal, InnoPranXL Propranolol 4946 N/A blocker Beta blocker NCT01504126 diagnosed epithelial ovarian cancer Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients N/A 0 Drug is beta-blocker. Clinical trial is testing it's ability to amplify taxol
NF-kappaB NFKB1 4790 Bortezomib PS-341, Velcade Bortezomib 387447 N/A inhibitor Proteosome and NF-kappaB inhibitor NCT01074411 Persistent or recurrent ovarian epithelial cancer Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer I 1
Trk NTRK1 4914 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
p53 P53 7157 Kevetrin Thioureidobutyronitrile granisetron 5284566 N/A activator p53 activator NCT01664000 Advanced solid tumors A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT00892736 Malignant solid tumors that did not respond to previous therapy ABT-888 in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT00989651 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01104259 BRCA1/2 hereditary ovarian cancer Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01145430 Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PHASE I STUDY OF ABT-888, PARP INHIBITOR, AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN RECURRENT GYNECOLOGIC CANCER AND BREAST CANCER I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01233505 Metastatic mucinous ovarian cancer and/or BRCA1/2 mutant Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors I 1
PARP1/2 PARP1 142 Olaparib AZD2281 Olaparib 23725625 N/A inhibitor PARP inhibitor NCT01237067 Ovarian cancer did not respond to conventional treatment Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers I 1
PARP1/2 PARP1 142 BMN-673 N/A 1207456-01-6 44819241 N/A inhibitor PARP inhibitor NCT01286987 Advanced ovarian cancer A Phase 1, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered BMN 673 in Patients With Advanced or Recurrent Solid Tumors I 1
PARP1/2 PARP1 142 ABT-767 N/A N/A N/A N/A inhibitor PARP inhibitor NCT01339650 Advanced BRCA1 or BRCA2-mutated solid tumors and high grade serous ovarian, fallopian tube, or primary peritoneal cancer A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01366144 Recurrent or stage IV ovarian cancer An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01434316 BRCA1/2 carriers, advanced solid tumors Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors I 1
PARP1/2 PARP1 142 Olaparib AZD2281 Olaparib 23725625 N/A inhibitor PARP inhibitor NCT01445418 Metastatic epithelial ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer who have failed prior therapy A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 Combined With Carboplatin in BRCA1/2 Familial Breast and Ovarian Cancer and Sporadic Triple Negative Breast and Ovarian Cancer I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01459380 Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer A Phase I Trial of Doxil ), Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer I 1
PARP1/2 PARP1 142 E7449 N/A N/A N/A N/A inhibitor PARP inhibitor NCT01618136 Advanced solid tumors An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors I 1
PARP1/2 PARP1 142 Olaparib AZD2281 Olaparib 23725625 N/A inhibitor PARP inhibitor NCT01623349 Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01749397 Recurrent (metastatic) epithelial ovarian cancer A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01853306 Platinum-sensitive recurrent BRCA1/2 mutated or G3 serous ovarian cancer A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib in Subjects With Solid Tumors I 1
PARP1/2 PARP1 142 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01012817 Platinum-refractory or recurrent (< 1yr after Pt treatment) ovarian epithelial or primary peritoneal cancer A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy I/II 1
PARP1/2 PARP1 142 Rucaparib AG014699, PF-01367338 RUCAPARIB 9931954 N/A inhibitor PARP inhibitor NCT01482715 gBRCA mutation ovarian cancer, platinum sensitive A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor I/II 1
PARP1/2 PARP1 142 Olaparib AZD2281 Olaparib 23725625 N/A inhibitor PARP inhibitor NCT01650376 Relapsed ovarian cancer Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients I/II 1
PARP1/2 PARP1 142 Niraparib MK4827 Niraparib 24958200 N/A inhibitor PARP inhibitor NCT01847274 Platinum-sensitive G3 serous (or germline BRCA) ovarian cancer A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer III 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT00892736 Malignant solid tumors that did not respond to previous therapy ABT-888 in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy I 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT00989651 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer I 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01104259 BRCA1/2 hereditary ovarian cancer Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer I 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01145430 Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PHASE I STUDY OF ABT-888, PARP INHIBITOR, AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN RECURRENT GYNECOLOGIC CANCER AND BREAST CANCER I 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01233505 Metastatic mucinous ovarian cancer and/or BRCA1/2 mutant Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors I 1
PARP1/2 PARP2 10038 Olaparib AZD2281 Olaparib 23725625 N/A inhibitor PARP inhibitor NCT01237067 Ovarian cancer did not respond to conventional treatment Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers I 1
PARP1/2 PARP2 10038 BMN-673 N/A 1207456-01-6 44819241 N/A inhibitor PARP inhibitor NCT01286987 Advanced ovarian cancer A Phase 1, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered BMN 673 in Patients With Advanced or Recurrent Solid Tumors I 1
PARP1/2 PARP2 10038 ABT-767 N/A N/A N/A N/A inhibitor PARP inhibitor NCT01339650 Advanced BRCA1 or BRCA2-mutated solid tumors and high grade serous ovarian, fallopian tube, or primary peritoneal cancer A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer I 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01366144 Recurrent or stage IV ovarian cancer An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors I 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01434316 BRCA1/2 carriers, advanced solid tumors Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors I 1
PARP1/2 PARP2 10038 Olaparib AZD2281 Olaparib 23725625 N/A inhibitor PARP inhibitor NCT01445418 Metastatic epithelial ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer who have failed prior therapy A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 Combined With Carboplatin in BRCA1/2 Familial Breast and Ovarian Cancer and Sporadic Triple Negative Breast and Ovarian Cancer I 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01459380 Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer A Phase I Trial of Doxil ), Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer I 1
PARP1/2 PARP2 10038 E7449 N/A N/A N/A N/A inhibitor PARP inhibitor NCT01618136 Advanced solid tumors An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors I 1
PARP1/2 PARP2 10038 Olaparib AZD2281 Olaparib 23725625 N/A inhibitor PARP inhibitor NCT01623349 Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer I 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01749397 Recurrent (metastatic) epithelial ovarian cancer A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers I 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01853306 Platinum-sensitive recurrent BRCA1/2 mutated or G3 serous ovarian cancer A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib in Subjects With Solid Tumors I 1
PARP1/2 PARP2 10038 Veliparib ABT-888 Veliparib 11960529 N/A inhibitor PARP inhibitor NCT01012817 Platinum-refractory or recurrent (< 1yr after Pt treatment) ovarian epithelial or primary peritoneal cancer A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy I/II 1
PARP1/2 PARP2 10038 Rucaparib AG014699, PF-01367338 RUCAPARIB 9931954 N/A inhibitor PARP inhibitor NCT01482715 gBRCA mutation ovarian cancer, platinum sensitive A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor I/II 1
PARP1/2 PARP2 10038 Olaparib AZD2281 Olaparib 23725625 N/A inhibitor PARP inhibitor NCT01650376 Relapsed ovarian cancer Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients I/II 1
PARP1/2 PARP2 10038 Niraparib MK4827 Niraparib 24958200 N/A inhibitor PARP inhibitor NCT01847274 Platinum-sensitive G3 serous (or germline BRCA) ovarian cancer A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer III 1
PD-1 receptor PDCD1 5133 BMS-936558 Anti-PD-1 human mab MDX-1106, MDX-1106, nivolumab, ONO-4538 Nivolumab N/A 160698453 blocker blocks PDL-1/2-dependent negative regulation of T NCT01714739 Advanced ovarian cancer A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination With Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors I 1
PDGFR PDGFRA 5156 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01438554 Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer I 1
PDGFR PDGFRA 5156 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01639911 Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
PDGFR PDGFRA 5156 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01639911 Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
PDGFR PDGFRA 5156 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
PDGFR PDGFRA 5156 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
PDGFR PDGFRA 5156 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01610206 Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
PDGFR PDGFRA 5156 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01669798 Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
PDGFRb PDGFRB 5159 Sorafenib BAY 43-9006, BAY 43-9006 tosylate salt, Nexavar Sorafenib 216239 N/A inhibitor RAF, VEGFR2, and PDGFR-beta inhibitors NCT01303341 Advanced solid tumors A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma I 1
PDGFR PDGFRB 5159 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01438554 Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer I 1
PDGFR PDGFRB 5159 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01639911 Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
PDGFR PDGFRB 5159 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01639911 Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors I 1
PDGFR PDGFRB 5159 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
PDGFR PDGFRB 5159 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
PDGFR PDGFRB 5159 Pazopanib Votrient Pazopani 10113978 N/A inhibitor VEFGR, c-Kit, and PDGFR inhibitor NCT01610206 Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
PDGFR PDGFRB 5159 Nintedanib BIBF 1120, Vargatef Nintedanib 56843413 N/A inhibitor VEGFR, FGFR, PDGFR, and FLT3 inhibitor NCT01669798 Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma II 1
PI3K PI3KCA 5290 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT00962611 Advanced Cancer BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer I 1
PI3K PI3KCA 5290 GDC-0941 N/A GDC-0941 17755052 N/A inhibitor pan-PI3K inhibitor NCT00996892 Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors i 1
PI3K alpha PI3KCA 5290 BYL719 P13K Inhibitor BYL719, phosphoinositide 3-Kinase inhibitor BYL719 BYL719 56649450 N/A inhibitor PI3K inhibitor NCT01219699 Advanced cancerwith PIK3CA gene alteration A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene I 1
PI3K PI3KCA 5290 GSK2126458 PI3K Inhibitor GSK2126458 GSK2126458 25167777 N/A inhibitor pan-PI3K inhibitor NCT01248858 Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. I 1
PI3K PI3KCA 5290 ZSTK474 N/A ZSTK474 11647372 N/A inhibitor pan-PI3K inhibitor NCT01280487 Advanced cancer A Safety Study of Oral ZSTK474 in Patients With Cancer I 1
PI3K PI3KCA 5290 BEZ235 NYP-BEZ235 NVP-BEZ235 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01343498 Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors I 1
PI3K PI3KCA 5290 PF-05212384, PF-04691502 PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587 PKI-587 44516953 N/A inhibitor PI3K/mTOR inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
PI3K PI3KCA 5290 PF-05212384, PF-04691502 PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587 PKI-591 44516953 N/A inhibitor PI3K/mTOR inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
PI3K PI3KCA 5290 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01363232 NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors I 1
PI3K PI3KCA 5290 DS-7423 N/A N/A N/A N/A inhibitor PI3K/mTOR inhibitor NCT01364844 Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors I 1
PI3K alpha PI3KCA 5290 BYL719 P13K Inhibitor BYL719, phosphoinositide 3-Kinase inhibitor BYL719 BYL719 56649450 N/A inhibitor PI3K inhibitor NCT01387321 Advanced Cancer A Study of BYL719 in Adult Patients With Advanced Solid Malignancies I 1
PI3K PI3KCA 5290 SAR245409 XL765, PI3K/mTOR Dual Kinase Inhibitor XL765 XL765 49867926 N/A inhibitor PI3K/mTOR inhibitor NCT01390818 Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors I 1
PI3K PI3KCA 5290 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01411410 Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy I 1
PI3K PI3KCA 5290 SAR245408 XL147 XL147 1893730 N/A inhibitor pan-PI3K inhibitor NCT01436565 Advanced Cancer A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers I 1
PI3K alpha PI3KCA 5290 MLN-1117 INK-1117 N/A N/A N/A inhibitor PI3K inhibitor NCT01449370 Advanced solid tumors A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease I 1
PI3K PI3KCA 5290 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01460537 Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer I 1
PI3K PI3KCA 5290 BEZ235 NYP-BEZ235 NVP-BEZ235 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01482156 Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors I 1
PI3K PI3KCA 5290 BEZ235 NYP-BEZ235 NVP-BEZ239 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01508104 Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors I 1
PI3K PI3KCA 5290 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01623349 Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer I 1
PI3K PI3KCA 5290 P7170 PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170 N/A N/A N/A inhibitor PI3K/mTOR/ALK-1/DNA-PK inhibitor NCT01762410 Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors. I 1
PI3K alpha PI3KCA 5290 BYL719 P13K Inhibitor BYL719, phosphoinositide 3-Kinase inhibitor BYL719 BYL719 56649450 N/A inhibitor PI3K inhibitor NCT01708161 Advanced ovarian cancer with PIK3CA mutation A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors I/II 1
PI3K PI3KCA 5290 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01392521 Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer Ib 1
PI3K alpha PI3KCA 5290 BYL719 P13K Inhibitor BYL719, phosphoinositide 3-Kinase inhibitor BYL719 BYL719 56649450 N/A inhibitor PI3K inhibitor NCT01449058 Advanced BRAF or KRAS mutant cancers A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Ib 1
PI3K PI3KCA 5290 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01550380 Advanced ovarian cancer w/ P13K pathway activation A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers II 1
PI3K PI3KCB 5291 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT00962611 Advanced Cancer BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer I 1
PI3K PI3KCB 5291 GDC-0941 N/A GDC-0942 17755052 N/A inhibitor pan-PI3K inhibitor NCT00996892 Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors i 1
PI3K PI3KCB 5291 GSK2126458 PI3K Inhibitor GSK2126458 GSK2126458 25167777 N/A inhibitor pan-PI3K inhibitor NCT01248858 Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. I 1
PI3K PI3KCB 5291 ZSTK474 N/A ZSTK474 11647372 N/A inhibitor pan-PI3K inhibitor NCT01280487 Advanced cancer A Safety Study of Oral ZSTK474 in Patients With Cancer I 1
PI3K PI3KCB 5291 BEZ235 NYP-BEZ235 NVP-BEZ236 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01343498 Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors I 1
PI3K PI3KCB 5291 PF-05212384, PF-04691502 PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587 PKI-588 44516953 N/A inhibitor PI3K/mTOR inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
PI3K PI3KCB 5291 PF-05212384, PF-04691502 PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587 PKI-592 44516953 N/A inhibitor PI3K/mTOR inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
PI3K PI3KCB 5291 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01363232 NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors I 1
PI3K PI3KCB 5291 DS-7423 N/A N/A N/A N/A inhibitor PI3K/mTOR inhibitor NCT01364844 Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors I 1
PI3K PI3KCB 5291 SAR245409 XL765, PI3K/mTOR Dual Kinase Inhibitor XL765 XL765 49867926 N/A inhibitor PI3K/mTOR inhibitor NCT01390818 Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors I 1
PI3K PI3KCB 5291 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01411410 Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy I 1
PI3K PI3KCB 5291 SAR245408 XL147 XL147 1893730 N/A inhibitor pan-PI3K inhibitor NCT01436565 Advanced Cancer A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers I 1
PI3K PI3KCB 5291 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01460537 Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer I 1
PI3K PI3KCB 5291 BEZ235 NYP-BEZ235 NVP-BEZ236 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01482156 Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors I 1
PI3K PI3KCB 5291 BEZ235 NYP-BEZ235 NVP-BEZ240 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01508104 Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors I 1
PI3K PI3KCB 5291 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01623349 Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer I 1
PI3K PI3KCB 5291 P7170 PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170 N/A N/A N/A inhibitor PI3K/mTOR/ALK-1/DNA-PK inhibitor NCT01762410 Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors. I 1
PI3K PI3KCB 5291 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01392521 Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer Ib 1
PI3K PI3KCB 5291 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01550380 Advanced ovarian cancer w/ P13K pathway activation A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers II 1
PI3K PI3KCD 5293 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT00962611 Advanced Cancer BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer I 1
PI3K PI3KCD 5293 GDC-0941 N/A GDC-0944 17755052 N/A inhibitor pan-PI3K inhibitor NCT00996892 Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors i 1
PI3K PI3KCD 5293 GSK2126458 PI3K Inhibitor GSK2126458 GSK2126458 25167777 N/A inhibitor pan-PI3K inhibitor NCT01248858 Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. I 1
PI3K PI3KCD 5293 ZSTK474 N/A ZSTK474 11647372 N/A inhibitor pan-PI3K inhibitor NCT01280487 Advanced cancer A Safety Study of Oral ZSTK474 in Patients With Cancer I 1
PI3K PI3KCD 5293 BEZ235 NYP-BEZ235 NVP-BEZ238 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01343498 Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors I 1
PI3K PI3KCD 5293 PF-05212384, PF-04691502 PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587 PKI-590 44516953 N/A inhibitor PI3K/mTOR inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
PI3K PI3KCD 5293 PF-05212384, PF-04691502 PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587 PKI-594 44516953 N/A inhibitor PI3K/mTOR inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
PI3K PI3KCD 5293 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01363232 NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors I 1
PI3K PI3KCD 5293 DS-7423 N/A N/A N/A N/A inhibitor PI3K/mTOR inhibitor NCT01364844 Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors I 1
PI3K PI3KCD 5293 SAR245409 XL765, PI3K/mTOR Dual Kinase Inhibitor XL765 XL765 49867926 N/A inhibitor PI3K/mTOR inhibitor NCT01390818 Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors I 1
PI3K PI3KCD 5293 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01411410 Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy I 1
PI3K PI3KCD 5293 SAR245408 XL147 XL147 1893730 N/A inhibitor pan-PI3K inhibitor NCT01436565 Advanced Cancer A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers I 1
PI3K PI3KCD 5293 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01460537 Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer I 1
PI3K PI3KCD 5293 BEZ235 NYP-BEZ235 NVP-BEZ238 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01482156 Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors I 1
PI3K PI3KCD 5293 BEZ235 NYP-BEZ235 NVP-BEZ242 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01508104 Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors I 1
PI3K PI3KCD 5293 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01623349 Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer I 1
PI3K PI3KCD 5293 P7170 PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170 N/A N/A N/A inhibitor PI3K/mTOR/ALK-1/DNA-PK inhibitor NCT01762410 Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors. I 1
PI3K PI3KCD 5293 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01392521 Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer Ib 1
PI3K PI3KCD 5293 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01550380 Advanced ovarian cancer w/ P13K pathway activation A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers II 1
PI3K PI3KCG 5294 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT00962611 Advanced Cancer BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer I 1
PI3K PI3KCG 5294 GDC-0941 N/A GDC-0943 17755052 N/A inhibitor pan-PI3K inhibitor NCT00996892 Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors i 1
PI3K PI3KCG 5294 GSK2126458 PI3K Inhibitor GSK2126458 GSK2126458 25167777 N/A inhibitor pan-PI3K inhibitor NCT01248858 Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. I 1
PI3K PI3KCG 5294 ZSTK474 N/A ZSTK474 11647372 N/A inhibitor pan-PI3K inhibitor NCT01280487 Advanced cancer A Safety Study of Oral ZSTK474 in Patients With Cancer I 1
PI3K PI3KCG 5294 BEZ235 NYP-BEZ235 NVP-BEZ237 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01343498 Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors I 1
PI3K PI3KCG 5294 PF-05212384, PF-04691502 PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587 PKI-589 44516953 N/A inhibitor PI3K/mTOR inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
PI3K PI3KCG 5294 PF-05212384, PF-04691502 PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587 PKI-593 44516953 N/A inhibitor PI3K/mTOR inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
PI3K PI3KCG 5294 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01363232 NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors I 1
PI3K PI3KCG 5294 DS-7423 N/A N/A N/A N/A inhibitor PI3K/mTOR inhibitor NCT01364844 Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors I 1
PI3K PI3KCG 5294 SAR245409 XL765, PI3K/mTOR Dual Kinase Inhibitor XL765 XL765 49867926 N/A inhibitor PI3K/mTOR inhibitor NCT01390818 Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors I 1
PI3K PI3KCG 5294 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01411410 Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy I 1
PI3K PI3KCG 5294 SAR245408 XL147 XL147 1893730 N/A inhibitor pan-PI3K inhibitor NCT01436565 Advanced Cancer A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers I 1
PI3K PI3KCG 5294 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01460537 Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer I 1
PI3K PI3KCG 5294 BEZ235 NYP-BEZ235 NVP-BEZ237 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01482156 Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors I 1
PI3K PI3KCG 5294 BEZ235 NYP-BEZ235 NVP-BEZ241 11977753 N/A inhibitor PI3K/mTOR inhibitor NCT01508104 Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors I 1
PI3K PI3KCG 5294 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01623349 Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer I 1
PI3K PI3KCG 5294 P7170 PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170 N/A N/A N/A inhibitor PI3K/mTOR/ALK-1/DNA-PK inhibitor NCT01762410 Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors. I 1
PI3K PI3KCG 5294 BAY 80-6946 N/A BCP9000383 N/A 144115686 inhibitor pan-PI3K inhibitor NCT01392521 Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer Ib 1
PI3K PI3KCG 5294 BKM120 NVP-BKM120 BKM120 16654980 N/A inhibitor pan-PI3K inhibitor NCT01550380 Advanced ovarian cancer w/ P13K pathway activation A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers II 1
AMPK PRKAA1 5562 Metformin Fortamet, Glucophage, Glumetza, Riomet Metformin hydrochloride 14219 N/A activator AMP-activated protein kinase (AMPK) activator NCT01529593 Advanced cancers Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers I 1
AMPK PRKAA1 5562 Metformin Fortamet, Glucophage, Glumetza, Riomet Metformin hydrochloride 14219 N/A activator AMP-activated protein kinase (AMPK) activator NCT01579812 Advanced ovarian cancer A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer II 1
AMPK PRKAA2 5563 Metformin Fortamet, Glucophage, Glumetza, Riomet Metformin hydrochloride 14219 N/A activator AMP-activated protein kinase (AMPK) activator NCT01529593 Advanced cancers Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers I 1
AMPK PRKAA2 5563 Metformin Fortamet, Glucophage, Glumetza, Riomet Metformin hydrochloride 14219 N/A activator AMP-activated protein kinase (AMPK) activator NCT01579812 Advanced ovarian cancer A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer II 1
AMPK PRKAB1 5564 Metformin Fortamet, Glucophage, Glumetza, Riomet Metformin hydrochloride 14219 N/A activator AMP-activated protein kinase (AMPK) activator NCT01529593 Advanced cancers Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers I 1
AMPK PRKAB1 5564 Metformin Fortamet, Glucophage, Glumetza, Riomet Metformin hydrochloride 14219 N/A activator AMP-activated protein kinase (AMPK) activator NCT01579812 Advanced ovarian cancer A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer II 1
Focal Adhesion Kinase (FAK) PTK2 5747 VS-6063 N/A N/A N/A N/A inhibitor FAK inhibitor NCT01778803 Adv or refractory ovarian cancer A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer I 1
RET RET 5976 Vandetanib AZD6474, Zactima, ZD6474 Vandetanib 3081361 N/A inhibitor VEGFR, EGFR, and RET inhibitor NCT01582191 Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer I 1
RET RET 5976 Dovitinib RTK inhibitor TKI258 Dovitinib 9886808 N/A inhibitor Multi-targeted RTK inhibitor NCT01831726 Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib I 1
RFC-1 RFC1 5981 Pralatrexate Folotyn, PDX Pralatrexate 148121 N/A inhibitor RFC-1 targeted DHFR inhibitor NCT01188876 Platinum sensitive relapsed ovarian cancer Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer I/II 1
Ribonucleotide reductase RRM1 6240 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01248949 Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors I 1
Ribonucleotide reductase RRM1 6240 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01352962 Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors I 1
Ribonucleotide reductase RRM1 6240 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01455532 Advanced solid tumors A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors I 1
Ribonucleotide reductase RRM1 6240 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01460537 Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer I 1
Ribonucleotide reductase RRM1 6240 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01624493 Relapsed ovarian cancer, platinum sensitive Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse I/II 1
Ribonucleotide reductase RRM1 6240 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01663857 Platinum sensitive ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer I/II 1
Ribonucleotide reductase RRM1 6240 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01131039 Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer II 1
Ribonucleotide reductase RRM1 6240 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01296035 Metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer. II 1
Ribonucleotide reductase RRM1 6240 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01610206 Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
Ribonucleotide reductase RRM2 6241 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01248949 Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors I 1
Ribonucleotide reductase RRM2 6241 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01352962 Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors I 1
Ribonucleotide reductase RRM2 6241 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01455532 Advanced solid tumors A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors I 1
Ribonucleotide reductase RRM2 6241 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01460537 Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer I 1
Ribonucleotide reductase RRM2 6241 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01624493 Relapsed ovarian cancer, platinum sensitive Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse I/II 1
Ribonucleotide reductase RRM2 6241 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01663857 Platinum sensitive ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer I/II 1
Ribonucleotide reductase RRM2 6241 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01131039 Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer II 1
Ribonucleotide reductase RRM2 6241 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01296035 Metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer. II 1
Ribonucleotide reductase RRM2 6241 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01610206 Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
Ribonucleotide reductase RRM2B 50484 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01248949 Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors I 1
Ribonucleotide reductase RRM2B 50484 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01352962 Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors I 1
Ribonucleotide reductase RRM2B 50484 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01455532 Advanced solid tumors A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors I 1
Ribonucleotide reductase RRM2B 50484 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01460537 Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer I 1
Ribonucleotide reductase RRM2B 50484 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01624493 Relapsed ovarian cancer, platinum sensitive Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse I/II 1
Ribonucleotide reductase RRM2B 50484 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01663857 Platinum sensitive ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer I/II 1
Ribonucleotide reductase RRM2B 50484 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01131039 Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer II 1
Ribonucleotide reductase RRM2B 50484 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01296035 Metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer. II 1
Ribonucleotide reductase RRM2B 50484 Gemcitabine Gemzar gemcitabine 60750 N/A inhibitor Ribonucleotide reductase and DNA synthesis inhibitor NCT01610206 Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
TROP2 [EGP-1 (epithelial glycoprotein-1)] TACSTD2 4070 IMMU-132 anti-TROP-2 Antibody-Drug Conjugate IMMU-132, hrS7-SN38 antibody drug conjugate N/A N/A N/A inhibitor TROP2-targeted TOPO I inhibitor NCT01631552 Metastatic ovarian cancer A Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer I 1
Tie-2 TEK 7010 Cabozantanib Cabozantinib, Cometriq Cabozantinib 25102847 N/A inhibitor RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor NCT01716715 Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER II 1
TLR8 TLR8 51311 VTX-2337 TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337 SureCN254984 16049404 N/A immunostimulator immunostimulator NCT01666444 Platinum resistant recurrent epithelial ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With doxil (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer II 1
TNF-alpha TNF 7124 Lenalidomide CC-5013, IMID-1, Revlimid lenalidomide 216326 N/A Anti-angiogenic. Anti-angiogenic. NCT01146795 Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer 0 1
TNF-alpha TNF 7124 Lenalidomide CC-5013, IMID-1, Revlimid lenalidomide 216326 N/A Anti-angiogenic. Anti-angiogenic. NCT01352962 Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors I 1
RANKL TNFSF11 8600 Denosumab N/A Denosumab N/A 135285955 antagonist RANKL antagonist NCT01624766 Advanced cancers A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies I 1
TOPO I TOP1 7150 Irinotecan Campothecin-11, Campto, Camptosar irinotecan 60838 N/A inhibitor TOPO I inhibitor NCT01347866 Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer I 1
TOPO I TOP1 7150 IMMU-132 anti-TROP-2 Antibody-Drug Conjugate IMMU-132, hrS7-SN38 antibody drug conjugate N/A N/A N/A inhibitor TROP2-targeted TOPO I inhibitor NCT01631552 Metastatic ovarian cancer A Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer I 1
TOPO I TOP1 7150 Topotecan Hycamptamine, Hycamtin, TOPO topotecan 60700 N/A inhibitor TOPO I inhibitor NCT01012817 Platinum-refractory or recurrent (< 1yr after Pt treatment) ovarian epithelial or primary peritoneal cancer A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy I/II 1
TOPO I TOP1 7150 Topotecan Hycamptamine, Hycamtin, TOPO topotecan 60700 N/A inhibitor TOPO I inhibitor NCT01696032 Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer I/II 1
TOPO I TOP1 7150 CRLX101 camptothecin-polymer conjugate IT-101, cyclodextrin-based polymer-camptothecin CRLX101, IT-101 Camptothecin 24360 N/A HIF-1alpha dual inhibitor of topoisomerase 1 and HIF-1alpha NCT01652079 Recurrent epithelial cancer A Phase II, 2-stage Trial of CRLX101-202 in Recurrent Ovarian, Tubal and Peritoneal Cancer II 1
TOPO I TOP1 7150 Irinotecan Campothecin-11, Campto, Camptosar irinotecan 60838 N/A inhibitor TOPO I inhibitor NCT01081262 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer III 1
TOPO I TOP1 7150 Topotecan Hycamptamine, Hycamtin, TOPO topotecan 60700 N/A inhibitor TOPO I inhibitor NCT01849874 Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer III 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01146795 Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer 0 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01145430 Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PHASE I STUDY OF ABT-888, PARP INHIBITOR, AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN RECURRENT GYNECOLOGIC CANCER AND BREAST CANCER I 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01281514 Platinum-sensitive ovarian cancer at first relapse PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE I 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01455532 Advanced solid tumors A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors I 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01459380 Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer A Phase I Trial of Doxil ), Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer I 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01489371 Recurrent epithelial ovarian cancer A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With doxil (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer I 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01715168 Recurrent ovarian cancer A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy I 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01815294 Advanced solid tumors A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer. I 1
TOPO II TOP2A 7153 Idronoxil Phenoxodiol Dehydroequol 219100 N/A inhibitor Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor NCT00303888 Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer I/II 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01696032 Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer I/II 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT00982631 Advanced or Recurrent Ovarian Cancer A Phase Ib Study of Combination of Temsirolimus (Torisel) and Pegylated Liposomal Doxorubicin (PLD, Doxil/ Caelyx) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer Ib 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT00003135 Metastatic ovarian cancer Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer II 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01666444 Platinum resistant recurrent epithelial ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With doxil (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer II 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01170650 primary or secondary platinum-resistant ovarian cancer Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) III 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01281254 Recurrent ovarian cancer A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer III 1
TOPO II TOP2A 7153 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01849874 Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer III 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01146795 Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer 0 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01145430 Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PHASE I STUDY OF ABT-888, PARP INHIBITOR, AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN RECURRENT GYNECOLOGIC CANCER AND BREAST CANCER I 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01281514 Platinum-sensitive ovarian cancer at first relapse PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE I 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01455532 Advanced solid tumors A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors I 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01459380 Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer A Phase I Trial of Doxil ), Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer I 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01489371 Recurrent epithelial ovarian cancer A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With doxil (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer I 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01715168 Recurrent ovarian cancer A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy I 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01815294 Advanced solid tumors A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer. I 1
TOPO II TOP2B 7155 Idronoxil Phenoxodiol Dehydroequol 219100 N/A inhibitor Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor NCT00303888 Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer I/II 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01485874 Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149 I/II 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01696032 Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer I/II 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT00982631 Advanced or Recurrent Ovarian Cancer A Phase Ib Study of Combination of Temsirolimus (Torisel) and Pegylated Liposomal Doxorubicin (PLD, Doxil/ Caelyx) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer Ib 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT00003135 Metastatic ovarian cancer Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer II 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01666444 Platinum resistant recurrent epithelial ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With doxil (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer II 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01170650 primary or secondary platinum-resistant ovarian cancer Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) III 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01281254 Recurrent ovarian cancer A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer III 1
TOPO II TOP2B 7155 Doxil Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride doxorubicin 31703 N/A inhibitor DNA intercalator and TOPO II inhibitor NCT01849874 Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer III 1
TRPV6 calcium channel TRPV6 55503 SOR-C13 N/A N/A N/A N/A inhibitor peptide TRPV6 inhibitor NCT01578564 Advanced ovarian cancer Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel I 1
Thymidylate synthase TYMS 7298 Fluorouracil 5-fluorouracil, 5-Fluracil, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Flurox, FU, Ribofluor, Timazin Fluorouracil 3385 N/A inhibitor RNA processing inhibitor and thymidylate synthase inhibitor NCT00610948 Advanced solid tumors A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies I 1
Thymidylate synthase TYMS 7298 Pemetrexed Alimta, Pemetrexed disodium MLS003106905 N/A 446556 inhibitor DHFR and Thymidylate synthase inhibitor NCT01172028 Advanced, recurrent solid tumor Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors I 1
Thymidylate synthase TYMS 7298 Capecitabine CAPE, Xeloda CAPECITABINE 60953 N/A inhibitor RNA processing inhibitor and thymidylate synthase inhibitor NCT01233505 Metastatic mucinous ovarian cancer and/or BRCA1/2 mutant Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors I 1
Thymidylate synthase TYMS 7298 Pemetrexed Alimta, Pemetrexed disodium MLS003106905 N/A 446556 inhibitor DHFR and Thymidylate synthase inhibitor NCT01567384 Advanced Cancer A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies I 1
Thymidylate synthase TYMS 7298 Floxuridine 5-FUDR, WR-138720 floxuridine 5790 N/A inhibitor RNA and DNA synthesis inhibitor NCT01749397 Recurrent (metastatic) epithelial ovarian cancer A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers I 1
Thymidylate synthase TYMS 7298 Fluorouracil 5-fluorouracil, 5-Fluracil, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Flurox, FU, Ribofluor, Timazin 5-Fluorouracil 3385 N/A inhibitor RNA processing inhibitor and thymidylate synthase inhibitor NCT00003135 Metastatic ovarian cancer Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer II 1
Thymidylate synthase TYMS 7298 Pemetrexed Alimta, Pemetrexed disodium MLS003106905 N/A 446556 inhibitor DHFR and Thymidylate synthase inhibitor NCT01001910 Platinum sensitive relapsed ovarian cancer Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer II 1
Thymidylate synthase TYMS 7298 Capecitabine CAPE, Xeloda CAPECITABINE 60953 N/A inhibitor RNA processing inhibitor and thymidylate synthase inhibitor NCT01081262 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer III 1
VEGF VEGFA 7422 Lenalidomide, Bevacizumab anti-VEGF monoclonal antibody, Avastin, CC-5013, IMID-1, Revlimid Lenalidomide 216326 N/A antagonist Anti-angiogenic., VEGF antagonist NCT01146795 Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer 0 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT00989651 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer I 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01248949 Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors I 1
VEGF VEGFA 7422 Lenalidomide CC-5013, IMID-1, Revlimid Lenalidomide 216326 N/A Anti-angiogenic. Anti-angiogenic. NCT01352962 Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors I 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01831089 Advanced solid tumors Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors I 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01010126 Locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor. Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor II 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01031381 Recurrent epithelial ovarian carcinoma Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV) II 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01097746 Newly diagnosed stage III, IV ovarian epithelial cancer First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer II 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01131039 Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer II 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01305213 Platinum sensitive recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT00565851 Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer III 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01081262 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer III 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01167712 Stage III, IV ovarian epithelial cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer III 1
VEGF VEGFA 7422 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01239732 Newly diagnosed advanced ovarian cncer Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma III 1
VEGF VEGFB 7423 Lenalidomide, Bevacizumab anti-VEGF monoclonal antibody, Avastin, CC-5013, IMID-1, Revlimid Lenalidomide 216326 N/A antagonist Anti-angiogenic., VEGF antagonist NCT01146795 Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer 0 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT00989651 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer I 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01248949 Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors I 1
VEGF VEGFB 7423 Lenalidomide CC-5013, IMID-1, Revlimid Lenalidomide 216326 N/A Anti-angiogenic. Anti-angiogenic. NCT01352962 Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors I 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01831089 Advanced solid tumors Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors I 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01010126 Locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor. Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor II 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01031381 Recurrent epithelial ovarian carcinoma Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV) II 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01097746 Newly diagnosed stage III, IV ovarian epithelial cancer First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer II 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01131039 Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer II 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01305213 Platinum sensitive recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT00565851 Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer III 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01081262 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer III 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01167712 Stage III, IV ovarian epithelial cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer III 1
VEGF VEGFB 7423 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01239732 Newly diagnosed advanced ovarian cncer Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma III 1
VEGF VEGFC 7424 Lenalidomide, Bevacizumab anti-VEGF monoclonal antibody, Avastin, CC-5013, IMID-1, Revlimid Lenalidomide 216326 N/A antagonist Anti-angiogenic., VEGF antagonist NCT01146795 Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer 0 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT00989651 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer I 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01248949 Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors I 1
VEGF VEGFC 7424 Lenalidomide CC-5013, IMID-1, Revlimid Lenalidomide 216326 N/A Anti-angiogenic. Anti-angiogenic. NCT01352962 Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors I 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01831089 Advanced solid tumors Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors I 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01010126 Locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor. Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor II 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01031381 Recurrent epithelial ovarian carcinoma Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV) II 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01097746 Newly diagnosed stage III, IV ovarian epithelial cancer First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer II 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01131039 Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer II 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01305213 Platinum sensitive recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma II 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT00565851 Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer III 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01081262 Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer III 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01167712 Stage III, IV ovarian epithelial cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer III 1
VEGF VEGFC 7424 Bevacizumab anti-VEGF monoclonal antibody, Avastin Bevacizumab N/A 50067187 antagonist VEGF antagonist NCT01239732 Newly diagnosed advanced ovarian cncer Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma III 1
WEE1 WEE1 7465 MK1775 N/A MK 1775 24856436 N/A inhibitor WEE1 inhibitor NCT01357161 Platinum-sensitive p53 mutant ovarian cancer A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer II 1
XIAP XIAP 331 Idronoxil Phenoxodiol Dehydroequol 219100 N/A inhibitor Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor NCT00303888 Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer I/II 1
Caspases XIAP 331 Idronoxil Phenoxodiol phenoxodiol 219100 N/A inhibitor Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor NCT00303888 Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer I/II 1